Champions Oncology, Inc.
CSBR · NASDAQ
4/30/2025 | 4/30/2024 | 4/30/2023 | 4/30/2022 | |
|---|---|---|---|---|
| Revenue | $57 | $50 | $54 | $49 |
| % Growth | 13.5% | -6.9% | 9.7% | – |
| Cost of Goods Sold | $30 | $29 | $30 | $24 |
| Gross Profit | $27 | $21 | $24 | $25 |
| % Margin | 47.3% | 41.4% | 45.2% | 51.9% |
| R&D Expenses | $7 | $10 | $12 | $9 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $15 | $18 | $17 | $15 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $22 | $28 | $29 | $25 |
| Operating Income | $5 | -$7 | -$4 | $1 |
| % Margin | 8.5% | -13.8% | -8.3% | 1.2% |
| Other Income/Exp. Net | -$0 | -$0 | -$1 | -$0 |
| Pre-Tax Income | $5 | -$7 | -$5 | $1 |
| Tax Expense | -$0 | -$0 | $0 | $0 |
| Net Income | $5 | -$7 | -$5 | $1 |
| % Margin | 8.3% | -14.5% | -9.9% | 1.1% |
| EPS | 0.34 | -0.54 | -0.39 | 0.042 |
| % Growth | 163% | -38.5% | -1,039.8% | – |
| EPS Diluted | 0.33 | -0.54 | -0.39 | 0.039 |
| Weighted Avg Shares Out | 14 | 14 | 14 | 13 |
| Weighted Avg Shares Out Dil | 14 | 14 | 14 | 14 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $3 | $2 |
| EBITDA | $6 | -$5 | -$2 | $3 |
| % Margin | 11.1% | -10.8% | -3.8% | 6.1% |